More deaths with Dynavax vaccine but overall rate low: FDA

(Reuters) - There were more deaths in patients taking Dynavax Technologies Corp's experimental hepatitis B vaccine than those taking a rival product, but the overall rate of death was low, a preliminary review by Food and Drug Administration reviewers concluded.